Cargando…

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance

Background: PET scans using FDG and somatostatin receptor imaging agents have both been used to study neuroendocrine tumours. Most reports have documented the sensitivity and specificity of each radiopharmaceutical independently, and even suggested the superiority of one over the other for different...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, David LH, Pavlakis, Nick, Schembri, Geoffrey P, Bernard, Elizabeth J, Hsiao, Edward, Hayes, Aimee, Barnes, Tristan, Diakos, Connie, Khasraw, Mustafa, Samra, Jaswinder, Eslick, Enid, Roach, Paul J, Engel, Alexander, Clarke, Stephen J, Bailey, Dale L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399582/ https://www.ncbi.nlm.nih.gov/pubmed/28435454 http://dx.doi.org/10.7150/thno.18068

Ejemplares similares

Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors
por: Mehta, Shreya, et al.
Publicado: (2015)

Dual [(68)Ga]DOTATATE and [(18)F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
por: Chan, David L., et al.
Publicado: (2022)

Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)
por: Wong, Matthew H., et al.
Publicado: (2016)

The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer
por: Maloney, Sarah, et al.
Publicado: (2023)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

Synchronous Operable Pancreatic and Breast Cancer Without Genetic Mutation: A Literature Review and Discussion
por: Ofri, Adam, et al.
Publicado: (2022)

The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors
por: Hindié, Elif
Publicado: (2017)

Pelvic MRI, FDG-PET/CT, and Somatostatin Receptor Scintigraphy Findings of Treatment-Related Neuroendocrine-Differentiated Prostate Cancer
por: Kitajima, Kazuhiro, et al.
Publicado: (2021)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer
por: Chan, Joseph C. Y., et al.
Publicado: (2017)

Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach
por: Gordon, S., et al.
Publicado: (2023)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
por: Kvols, L. K., et al.
Publicado: (1992)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

A pictoral review on somatostatin receptor scintigraphy in neuroendocrine tumors: The role of multimodality imaging with SRS and GLUT receptor imaging with FDG PET-CT
por: Shah, Sneha, et al.
Publicado: (2012)

Tumor sidedness is not an independent prognostic marker of colorectal cancer patients undergoing curative resection: A retrospective cohort study
por: Chan, Joseph Chung Yan, et al.
Publicado: (2019)

Serum bicarbonate is a marker of peri-operative mortality but is not associated with long term survival in colorectal cancer
por: Chan, Joseph Chung Yan, et al.
Publicado: (2020)

Correction: Serum bicarbonate is a marker of peri-operative mortality but is not associated with long term survival in colorectal cancer
por: Chan, Joseph Chung Yan, et al.
Publicado: (2021)

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors
por: Wang, Ling, et al.
Publicado: (2013)

Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer
por: Mori, Hiroshi, et al.
Publicado: (2018)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix
por: Saponjski, Jelena, et al.
Publicado: (2020)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
por: Wiesli, Peter, et al.
Publicado: (2019)

Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms
por: Inaba, Yoshitaka, et al.
Publicado: (2022)

Multivisceral resection of pancreatic neuroendocrine tumours: a report of two cases
por: Gundara, Justin S, et al.
Publicado: (2011)

Somatostatin receptors on neuroendocrine tumors--a way to intraoperative diagnosis and localization.
por: Ahlman, H., et al.
Publicado: (1994)

Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization.
por: Jensen, R. T., et al.
Publicado: (1997)

Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
por: Ge, Wenhao, et al.
Publicado: (2018)

Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells
por: Krug, Sebastian, et al.
Publicado: (2019)

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
por: Hu, Yuheng, et al.
Publicado: (2021)

Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
por: Mandriani, Barbara, et al.
Publicado: (2022)

Patient And Nurse Experience Of Using Somatostatin Analogues To Treat Gastroenteropancreatic Neuroendocrine Tumors: Results Of The Somatostatin Treatment Experience Trial (STREET)
por: Ström, Torbjörn, et al.
Publicado: (2019)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

Combined multiphoton microscopy and somatostatin receptor type 2 imaging of pancreatic neuroendocrine tumors
por: Daigle, Noelle, et al.
Publicado: (2023)

SAT-LB24 Association of Expression of Somatostatin Receptor 2 Subtype in Non-Pituitary Neuroendocrine Tumors With Response to Treatment With Somatostatin Analogues
por: Siddiqui, Abdullah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jd9p7msj13da8c3lu4ar697thr